Federal Register / Vol. 83, No. 152 / Tuesday, August 7, 2018 / Notices 38707 

Program (CICP) to provide benefits to 

certain individuals or estates of 

individuals who sustain a covered 

serious physical injury as the direct 

result of the administration or use of the 

Covered Countermeasures, and benefits 

to certain survivors of individuals who 

die as a direct result of the 

administration or use of the Covered 

Countermeasures. The causal 

connection between the countermeasure 

and the serious physical injury must be 

supported by compelling, reliable, valid, 

medical and scientific evidence in order 

for the individual to be considered for 

compensation. The CICP is 

administered by the Health Resources 

and Services Administration, within the 

Department of Health and Human 

Services. Information about the CICP is 

available at the toll-free number 1–855– 

266–2427 or http://www.hrsa.gov/cicp/. 

XV. Amendments 

42 U.S.C. 247d–6d(b)(4) 

Amendments to this Declaration will 

be published in the Federal Register. 

Authority: 42 U.S.C. 247d–6d. 

Dated: August 1, 2018. 

Alex M. Azar II 

Secretary, Department of Health and Human 

Services. 

[FR Doc. 2018–16856 Filed 8–6–18; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Initial Review Group; Clinical Aging 

Review Committee NIA–C. 

Date: September 27–28, 2018. 

Time: 3:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Rd., Bethesda, MD 20814. 

Contact Person: Alicja L. Markowska, 

Ph.D., DSC, National Institute on Aging, 

National Institutes of Health, Gateway 

Building 2C212, 7201 Wisconsin Avenue, 

Bethesda, MD 20892, 301–496–9666, 

markowsa@nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: August 1, 2018. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–16787 Filed 8–6–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information may be obtained 

by emailing the indicated licensing 

contact at the National Heart, Lung, and 

Blood, Office of Technology Transfer 

and Development Office of Technology 

Transfer, 31 Center Drive Room 4A29, 

MSC2479, Bethesda, MD 20892–2479; 

telephone: 301–402–5579. A signed 

Confidential Disclosure Agreement may 

be required to receive any unpublished 

information. 

SUPPLEMENTARY INFORMATION: This 

notice is in accordance with 35 U.S.C. 

209 and 37 CFR part 404 to achieve 

commercialization of results of 

federally-funded research and 

development. 

Technology description follows. 

Neuroendocrine Tumor Evans Blue 

Containing Radiotherapeutics 

The invention pertains to a 

radiotherapeutic against neuroendocrine 

tumors that express somatostatin 

receptor. Radionuclide therapies 

directed against tumors that express 

somatostatin receptors (SSTRs) have 

proven effective for the treatment of 

advanced, low- to intermediate-grade 

neuroendocrine tumors. The subject 

radiotherapeutic covered by the subject 

patent estate includes a somatostatin 

(SST) peptide derivative like octreotate 

(TATE), conjugated to an Evans Blue 

(EB) analog, and further chelated via 

DOTA to therapeutic radionuclide177Lu, 

a beta emitter. The EB analog reversibly 

binds to circulating serum albumin and 

improves the pharmacokinetics of SST 

peptide derivatives and reduce peptidereceptor radionuclide therapy toxicity. 

EB analog conjugated to octreotate (EB– 

DOTATATE) has been shown by the 

inventors to provide reversible albumin 

binding in vivo and extended half-life in 

circulation. When EB–TATE is slowly 

released into the tumor 

microenvironment, tumor uptake and 

internalization into SSTR positive 

tumors resulted in delivery of 

radioactive particles and tumor cell 

killing. EB–TATE displayed 

significantly more favorable 

pharmacokinetics than TATE alone by 

achieving higher tumor to non-tumor 

penetration as evidenced by positron 

emission tomography. 

Potential Commercial Applications: 

• Cancer therapeutics 

• Higher stability/Lower toxicity 

Development Stage: 

• Early stage 

Inventors: Xiaoyuan Chen and Orit 

Jacobson Weiss (both of NIBIB). 

Intellectual Property: HHS Reference 

No. E–150–2016–1; International Patent 

Application PCT/US2017/031696. 

Licensing Contact: Michael 

Shmilovich, Esq, CLP; 301–435–5019; 

shmilovm@mail.nih.gov. 

Dated: July 20, 2018. 

Michael Shmilovich, 

Senior Licensing and Patenting Manager, 

National Heart, Lung, and Blood Institute, 

Office of Technology Transfer and 

Development. 

[FR Doc. 2018–16839 Filed 8–6–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive Patent 

License: Treatment of Type I Diabetes 

and its Comorbidities 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Heart, Lung and 

Blood Institute (NHLBI), National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 

patent License to Inversago Pharma, 

Inc., located in Montreal, Quebec, 

Canada, to practice the inventions 

embodied in the patent applications 


daltland on DSKBBV9HB2PROD with NOTICES